(3R,3aR,4S,4aR,7R,8aR,9aR)-7-((Ethoxycarbonyl)amino)-3-methyl-1-oxododecahydronaphtho[2,3-c]furan-4-carboxylic acid

(3R,3aR,4S,4aR,7R,8aR,9aR)-7-((Ethoxycarbonyl)amino)-3-methyl-1-oxododecahydronaphtho[2,3-c]furan-4-carboxylic acid

Intermediate for Vorapaxar. Vorapaxar (trade name: Zontivity) is a thrombin receptor (protease-activated receptor, PAR-1) antagonist. Vorapaxar is a new anti-platelet drug that and is used for persons with a history of myocardial infarction (heart attack) or persons with peripheral arterial disease. Vorapaxar has been approved by the U.S Food and Drug Administration on May 5, 2014.

Specifications

Product Name:                  (3R,3aR,4S,4aR,7R,8aR,9aR)-7-((Ethoxycarbonyl)amino)-3-methyl-1-oxododecahydronaphtho[2,3-c]furan-4-carboxylic acid

Synonyms:                         N/A

CAS Number:                     900161-13-9

Molecular Weight:            339.3876

Molecular Formula:          C17H25NO6

Purity (HPLC):                     ≥95%

Shipping Conditions:         Room temperature.

Storage Conditions:           Refrigerated.

Regulatory Statement:      For Research Use Only.

SMILES:                               O=C(O[C@@H]3C)[C@]([C@]3([H])[C@H]2[C@@](O)=O)([H])C[C@@]1([H])[C@@]2([H])CC[C@@H](NC(OCC)=O)C1

  • $3,323.00
  • Ex Tax: $3,323.00

Available Options